SABCS 2022 Day 2 Press Conference December 7, 2022.
Ian E. Krop, MD, PhD from Yale University discusses Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02
Sara Hurvitz, MD from UCLA Health discusses Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Aditya Bardia, MD, MPH from Massachusetts General Hospital discusses TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer